Posts Tagged ‘Healthcare’
DayOne Tech Accelerator presents its first cohort
The DayOne Tech Accelerator in the Canton of Jura has just announced its winners. Three Medtech startups are starting a 12-month programme. Experts will help to push them to a higher level. CNS Therapy (Zug): Drug-free pain treatment The company has developed the ability to treat chronic pain patients using neuromodulation and behavioral therapy.…
Read MoreAC BioScience closes a 4th seed-round of CHF 2.5 million
AC BioScience, a Biopôle-based clinical-stage biotech company pioneering the development of novel therapies in immuno-oncology and tumour vascular normalization, announces a fourth Seed Round for CHF 2.5 million. Founded by Andreas Schlaepfer and Professor Christian Auclair, AC BioSciences develops personalized molecular therapies designed to optimize efficiency or bolster the therapeutic benefit for particular groups…
Read MoreAlcon buys Aerial Pharmaceutics for $770 million
Ophthalmic devices and Geneva-based Alcon has reached an agreement to acquire North Carolina-based Aerie Pharmaceuticals for $770 million (743.1 million francs). The transaction will strengthen the former Novartis subsidiary’s position in the fields of glaucoma and dry eye. Alcon will acquire Rocklatan (netarsudil and latanoproste) and Rhopressa (netarsudil), which are approved for the reduction…
Read MoreNovartis to list its subsidiary Sandoz on the stock exchange
Under consideration since 2021, the details of the demerger of Sandoz, the generic drug arm of Swiss pharmaceutical giant Novartis, are becoming clearer. It will not be sold, but listed on the Swiss and US stock exchanges in the second half of 2023. Sandoz will be the number one listed generic player in Europe. …
Read MoreTwiice’s exoskeleton allows paralysed people to walk again
Vaud-based and EPFL spin-off startup TWIICE receives a CHF 100 000 seed loan from FIT Every year, around 250,000 people suffer a spinal cord injury resulting in permanent paraplegia. The primary means of mobility for people with paraplegia is the wheelchair, which exposes users to long-term health problems such as loss of bone density,…
Read MoreObsEva plans job cuts
The ObsEva laboratory is to engage in a vast restructuring process in the face of difficulties encountered with the FDA with its drug in development Linzagolix. Job cuts might be on the agenda. The US Drug Administration (FDA) agreed in November 2021 to review the application for the drug to treat heavy periods associated with…
Read MoreDexter®, the Swiss surgery robot, makes its way to Germany
The Dexter® on-demand robotic surgery system created by the swiss company Distalmotion is now used by the Department for Women’s Health and Gynecology at the University Hospital Tübingen in Germany. Prof. Dr. med. Diethelm Wallwiener, Prof. Dr. med. Sara Brucker, Prof. Dr. med. Bernhard Krämer and their teams used theDexter robot in several surgical…
Read MoreDebiopharm signs an new IDEAL agreement with the University of Geneva
Debiopharms and UNIGE want to fight together against cancer and drug-resistant bacterial infections JULY 25, 2022 Debiopharm, a Swiss biopharmaceutical company based in Lausanne, signed of a new agreement as part of its IDEAL (Innovation Debiopharm Academia Léman) initiative with the University of Geneva (UNIGE). The UNIGE Faculty of Medicine has become a partner of the IDEAL program…
Read MoreNestlé Health Science invests EUR 40 million in Enterome
Nestlé Health Science has signed a collaboration agreement with French company Enterome to target food allergies and chronic intestinal diseases Enterome develops new treatments for cancer and autoimmune diseases based on its unique knowledge of the microbiota. With Nestlé Health Science, the french company intends to work on the development of an experimental treatment,…
Read MoreADC Therapeutics signs multi-million dollar licensing agreement with Sobi
The swiss and the Swedish companies partner for the development and commercialization of ZYNLONTA®, a drug for hematologic and solid tumors ADC Therapeutics SA has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the…
Read More